Liquidia (NASDAQ:LQDA) Coverage Initiated at Scotiabank

Equities research analysts at Scotiabank assumed coverage on shares of Liquidia (NASDAQ:LQDA) in a research note issued to investors on Wednesday, Marketbeat.com reports. The brokerage set a “sector outperform” rating and a $30.00 price target on the stock. Scotiabank’s target price points to a potential upside of 161.78% from the company’s current price.

A number of other research analysts have also recently commented on LQDA. Lifesci Capital began coverage on Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target on the stock. HC Wainwright decreased their price target on Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Bank of America decreased their price target on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Needham & Company LLC restated a “buy” rating and issued a $25.00 price target on shares of Liquidia in a research report on Monday, August 19th. Finally, Raymond James upgraded Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Liquidia Stock Performance

LQDA opened at $11.46 on Wednesday. Liquidia has a fifty-two week low of $5.71 and a fifty-two week high of $16.99. The company has a market capitalization of $875.70 million, a P/E ratio of -7.35 and a beta of 0.22. The stock has a fifty day moving average of $10.42 and a 200-day moving average of $11.97.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The company had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. On average, equities research analysts predict that Liquidia will post -1.69 earnings per share for the current fiscal year.

Insider Transactions at Liquidia

In other news, General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $28,619.36. Following the completion of the transaction, the general counsel now owns 486,048 shares of the company’s stock, valued at $5,399,993.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $28,619.36. Following the completion of the transaction, the general counsel now owns 486,048 shares of the company’s stock, valued at $5,399,993.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the transaction, the insider now directly owns 207,383 shares of the company’s stock, valued at $2,304,025.13. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,858 shares of company stock worth $228,724. Insiders own 31.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC acquired a new position in shares of Liquidia in the second quarter valued at approximately $27,000. Hilltop National Bank bought a new stake in Liquidia in the second quarter valued at approximately $33,000. Deuterium Capital Management LLC bought a new stake in Liquidia in the second quarter valued at approximately $120,000. DMC Group LLC bought a new stake in Liquidia in the second quarter valued at approximately $122,000. Finally, Whitcomb & Hess Inc. bought a new stake in Liquidia in the second quarter valued at approximately $126,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).